Aldagen

Aldagen develops regenerative cell therapies for inherited metabolic diseases, leukemia, critical limb ischemia and ischemic heart failure.

Launch date

2001

Employees

Market cap

Enterprise valuation

Durham North Carolina (HQ)

Date	Investors	Amount	Round
-	New Markets Venture Partners	N/A	-
Jan 2000	Duke University	N/A	Spinout
Feb 2002	Intersouth Partners Harbert Growth Partners	$6.0m	Series A
Mar 2003	Intersouth Partners Harbert Growth Partners	$4.9m	Series B
Dec 2006	Intersouth Partners Tall Oaks Capital Partners Harbert Growth Partners	$14.3m	Series C
Sep 2007	CNF Investments LLC Tullis Health Investors Intersouth Partners Harbert Growth Partners CNF Investments, LLC	$9.0m	Series C
Apr 2008	Tullis Health Investors Intersouth Partners Aurora Funds Harbert Growth Partners	$18.4m	Series D
Oct 2009	N/A	$7.3m	Debt
Jun 2011	N/A	$1.1m	Debt
Jan 2012	N/A	$585k	Debt
Total Funding		CAD71.7m

Tech stackLearn more about the technologies and tools that this company uses.

Recent News about Aldagen